We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseas... Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. Show more
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell...
ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024Progress of Radio-DARPin Therapy (RDT) platform: Improved...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions